Guangyu Y. An

Beijing, CN 
Beijing, CN 

Overview

Guangyu An practices practicing medicine in Beijing, China.

Their clinical expertise encompasses Parathyroid Cancer, Parathyroid Adenoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer.

They are actively involved in clinical research, co-authoring 99 peer reviewed articles and participating in 3 clinical trials.

Locations

Beijing, China
Other Locations
State Key Laboratory Of Environmental Aquatic Chemistry, No. 18, Shuangqing Road, Haidian, 100085, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
View 2 Less Clinical Trials

99 Total Publications

Advanced Lung Cancer Inflammation Index as a Prognostic Inflammation-Nutrition Marker in Appendiceal High-Grade Pseudomyxoma Peritonei: A 10-Year Single-Center Study.
Advanced Lung Cancer Inflammation Index as a Prognostic Inflammation-Nutrition Marker in Appendiceal High-Grade Pseudomyxoma Peritonei: A 10-Year Single-Center Study.
Journal: ANZ journal of surgery
Published: May 13, 2026

Frequently Asked Questions about Guangyu Y. An

Is Guangyu Y. An a top-rated expert for Parathyroid Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Guangyu Y. An is classified as an Experienced expert for Parathyroid Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Guangyu Y. An participate in research or clinical trials?

Yes. Guangyu Y. An has published 99 articles and abstracts on conditions like Parathyroid Cancer. You can view a list of Guangyu Y. An's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find An's expertise for a condition
ConditionClose
        View All 18 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile